Rectal Cancer Deaths Statistics in US 2026 | Key Facts

What is Rectal Cancer?

Rectal cancer is a malignancy that originates in the cells lining the rectum — the final several inches of the large intestine, just above the anus. While it is closely related to colon cancer and the two are frequently studied together under the umbrella term colorectal cancer (CRC), rectal cancer carries its own distinct epidemiology, treatment landscape, and mortality profile that demands separate attention. In 2026, the United States is grappling with a deeply troubling trend that has upended decades of progress: after years of overall decline, rectal cancer incidence is rising again — and it is doing so fastest among younger Americans who were never historically considered a high-risk population. According to the landmark Colorectal Cancer Statistics, 2026 report published on March 2, 2026 in CA: A Cancer Journal for Clinicians — the American Cancer Society’s flagship peer-reviewed journal — rectal cancer now accounts for 32% of all colorectal cancer diagnoses, up sharply from 27% in the mid-2000s, driven by a surge in distal colon and rectal tumors in adults under 65.

What makes the rectal cancer death statistics in the US in 2026 so urgent is not merely the raw numbers, but the demographic shift behind them. For the first time in the modern era, colorectal cancer — with rectal tumors driving much of the increase — is the number one cause of cancer-related death in Americans under 50. This is a generation that, by traditional screening guidelines, was not even considered for routine colonoscopy until recently, which helps explain why roughly three in four colorectal cancers in adults younger than 50 are diagnosed at an advanced stage, when the disease is far harder to treat and survival odds drop precipitously. The causes of this shift remain under active investigation, with researchers pointing to ultraprocessed food consumption, the gut microbiome, microplastics exposure, antibiotic use, and other contemporary lifestyle factors as likely contributors — though no single definitive cause has yet been established.

Key Facts About Rectal Cancer Deaths in the US 2026

Source: American Cancer Society Colorectal Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians, March 2, 2026); NCI SEER Program (seer.cancer.gov, 2024–2025 data); ACS Cancer Facts & Figures 2026; ACS Colorectal Cancer Facts & Figures 2023–2025; Colorectal Cancer Alliance, 2026

The facts table above tells a story of contradiction that few areas of American oncology can match: a cancer that has been getting rarer among older adults for decades while simultaneously becoming more deadly and more common among younger Americans. The 49,990 estimated new rectal cancer cases in the US in 2026 — with men accounting for 57% of those diagnoses — represents a patient population that skews younger than it did even a generation ago. The fact that 22% of all CRC diagnoses in 2022 occurred in adults under 55 — exactly double the proportion from 1995 — while the population of that age group actually shrank as a share of the total US population, makes the underlying trend even more alarming. This is not a statistical artifact of a larger young population. Something is genuinely driving more rectal and distal colon cancers in younger Americans, and researchers are still racing to find the answer.

The 56% decline in CRC death rates from 1970 to 2020 — from 29.2 to 12.6 per 100,000 — is a genuine public health triumph built on decades of investment in screening, surgical advances, and increasingly effective treatment regimens. But the pace of that decline has measurably slowed to around 2% per year over the past decade, compared to 3–4% annually during the 2000s. That deceleration, driven in large part by rising rates in younger and middle-aged adults, is the defining warning signal embedded in the rectal cancer death statistics for the US in 2026. With just 37% screening prevalence among adults under 50 and 75% of young-adult CRC cases diagnosed at advanced stage, the pipeline of preventable deaths in younger Americans is one of the most pressing unresolved challenges in US oncology today.

Rectal Cancer Survival Rates by Stage in the US 2026

Source: ACS Colorectal Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians, March 2, 2026 — PMC/NIH); ACS Cancer Facts & Figures 2026; NCI SEER Program; PMC — Epidemiology of Colorectal Cancer (2019); AJMC 2026 CRC Report Summary

Stage at diagnosis remains, without question, the single most powerful predictor of whether a person with rectal cancer in the United States will survive. The gulf between a 91% five-year survival rate for localized disease versus 15% for distant-stage disease is not just a statistic — it is the central argument for why colorectal cancer screening at the right age, and with adequate follow-through, can be literally life-saving. The most meaningful progress embedded in the 2026 survival statistics is the improvement in distant-stage rectal cancer survival from 8% to 18% since the mid-1990s. That doubling — achieved through improved surgical techniques, better imaging for staging, advances in the treatment of liver metastases (the most common site of rectal cancer spread), and refinements in chemotherapy, targeted therapy, and immunotherapy — represents genuine scientific progress, even if an 18% five-year survival rate for metastatic rectal cancer still reflects a disease that is extraordinarily difficult to treat once it has spread.

The survival data for young adults with rectal cancer is simultaneously hopeful and urgent. A 95% five-year survival rate exists for localized-stage CRC in adults under 50 — but the catch is that only a small minority of young patients are diagnosed at that stage. The 75% advanced-stage diagnosis rate among adults under 50 reflects a systemic failure of early detection. When cancer is found at the regional or distant stage in young patients, survival odds drop sharply from that 95% benchmark. This is why the American Cancer Society updated its guidelines to recommend that average-risk adults begin CRC screening at age 45 — a change that, if broadly implemented, could shift meaningful numbers of young patients from late-stage to early-stage diagnosis. Yet with only 37% screening prevalence among under-50 adults, that potential remains largely unrealized in practice.

Rectal Cancer Incidence & Death Trends in the US 2026

Source: ACS Colorectal Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians, March 2026); NCI SEER Stat Facts: Colorectal Cancer (seer.cancer.gov, 2024–2025 data); ACS CRC Facts & Figures 2023–2025; CDC WONDER mortality data analysis (Newswise/peer-reviewed, 2022)

The incidence and mortality trends together define why rectal cancer in the US in 2026 occupies a uniquely concerning position in the national cancer landscape. On the surface, the headline numbers look like continued progress: the overall CRC incidence rate fell by 0.9% per year from 2013 to 2022, and the CRC death rate stands at 12.9 per 100,000 — dramatically lower than the 29.2 per 100,000 recorded in 1970. But these averages mask a deeply troubling divergence by age group. In adults 65 and older — the population routinely screened for decades — incidence is declining at 2.5% per year, reflecting the power of colonoscopy to detect and remove precancerous polyps before they become cancer. In adults aged 20–49, however, incidence is rising at 3% per year, and in adults aged 50–64, it is rising at 0.4% per year. The engine of this rise, as confirmed by the ACS Colorectal Cancer Statistics 2026 report published in March 2026, is distal colon and rectal tumors — exactly the location profile of rectal cancer.

The CDC WONDER mortality analysis covering 1999 to 2020 adds crucial historical texture: of the 1,166,099 total CRC deaths in that period, 148,862 (12.77%) were specifically attributed to rectal cancer. Men had a consistently higher age-adjusted mortality rate from CRC than women — 23.90 per 100,000 vs. 17.03 per 100,000 — a gap that persists across age groups and racial/ethnic categories. The fact that nearly one-third of all CRC deaths in 2026 will occur in adults under 65 represents a generational shift in who is dying from this disease in America, and it is a shift that existing screening infrastructure — designed for an older, higher-risk population — is not yet adequately equipped to address.

Rectal Cancer Racial & Ethnic Disparities in Deaths, US 2026

Source: ACS Cancer Treatment and Survivorship Statistics 2025 (PMC/NIH); ACS Colorectal Cancer Statistics 2026; CDC WONDER mortality analysis (1999–2020, peer-reviewed via Newswise); ACS CRC Facts & Figures 2023–2025; AJMC CRC 2026 Report Summary; PMC — Racial and Ethnic Disparities in CRC Incidence and Mortality (2022); PMC — Disparities in Hispanic vs. White CRC (2019)

The racial and ethnic disparities data embedded in US rectal cancer death statistics for 2026 reflect two distinct but intertwined realities: biological differences in tumor characteristics and, far more significantly, structural inequities in access to screening, timely surgery, and high-quality follow-up care. The 25-percentage-point gap in surgical treatment rates between Black and White patients with stage I rectal cancer — 39% vs. 64% — is one of the most documented and damning inequities in American oncology. Research consistently shows that Black patients are less likely to receive surgery for early-stage rectal cancers and less likely to receive sphincter-preserving procedures, which are associated with better outcomes and quality of life. These are not differences that arise from biological factors; they reflect documented systemic barriers including medical mistrust, insurance gaps, concentration of care in community hospitals rather than academic centers with specialized rectal surgery expertise, and implicit bias in treatment recommendations.

The trajectory of the American Indian and Alaska Native (AIAN) population within US rectal cancer statistics is particularly alarming. The AIAN-White colorectal cancer incidence disparity has not only persisted but actually widened from 39% to 48% between 2013 and 2022, even as the Black-White disparity has narrowed from 22% to 11% during the same period. Alaska Native individuals in particular face what researchers describe as the highest CRC incidence and mortality in the world — a distinction driven by a combination of dietary patterns, geographic isolation limiting access to screening and specialty care, and chronic underfunding of Indian Health Service facilities. The 52% rise in rectal cancer incidence among Hispanic Americans between 2000 and 2010, during a period when rates were falling in White Americans, adds another dimension to the equity crisis and reflects rapidly changing dietary patterns within a population that had historically shown lower CRC rates.

Rectal Cancer Screening & Risk Factors in the US 2026

Source: ACS Colorectal Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians, March 2, 2026); NCI SEER Stat Facts: Colorectal Cancer; ACS Cancer.org Key Statistics 2026; Kaiser Permanente/Exact Sciences retrospective cohort (2006–2012); Cancer Research Institute — Colorectal Cancer Awareness Month 2026; ACS CRC Risk Factors 2026

The screening data table above crystallizes perhaps the single most actionable insight within the entire landscape of rectal cancer deaths in the US in 2026: the problem of late-stage diagnosis in younger Americans is not fundamentally a treatment problem — it is a detection problem. The 76% of CRC deaths that occurred in patients who were not up to date with screening (from the Kaiser Permanente retrospective cohort) makes the case in stark numerical terms. Colonoscopy, when performed on schedule, reduces CRC incidence by approximately 40% and mortality by approximately 60% — numbers that few medical interventions of any kind can match. Yet among adults under 50, only 37% are screened, and even among those who do receive a positive stool test result, follow-up colonoscopy is frequently delayed, effectively negating the benefit of the initial test.

The emerging research into novel risk factors for early-onset rectal cancer is one of the most active frontiers in American oncology heading into 2026. Established risk factors like red meat consumption, processed meat, alcohol, and physical inactivity do not adequately explain the specific rise in distal colon and rectal tumors in younger birth cohorts. Researchers at the American Cancer Society, as stated explicitly in the Colorectal Cancer Statistics 2026 report, are increasingly focused on ultraprocessed food consumption, microplastics exposure, antibiotic-related gut microbiome disruption, and other contemporary environmental factors. Notably, obesity and physical inactivity — traditionally the most-cited lifestyle risks — are more strongly associated with colon tumors than rectal tumors, suggesting that the specific rise in rectal cancer in younger Americans likely involves different or additional biological pathways. Identifying those pathways is essential to developing targeted prevention strategies and, ultimately, reversing the rising death toll in a generation of Americans that should be at the peak of their health.

Rectal Cancer Treatment & Surgery Disparities in the US 2026

Source: ACS Cancer Treatment and Survivorship Statistics 2025 (PMC/NIH, published May 2025); ACS Colorectal Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians); AACR Cancer Progress Report 2025; ACS Cancer Disparities Chartbook (ACS CAN, April 2026)

The treatment and surgery data table tells the same disparity story that runs through every dimension of rectal cancer death statistics in the US — but here it becomes concrete and clinical. A 25-percentage-point gap in surgical treatment rates between Black and White patients with early-stage rectal cancer is not a subtle statistical difference; it represents thousands of patients each year who are not receiving the surgery that offers their best — often their only — path to cure. The ACS Cancer Treatment and Survivorship Statistics 2025 report documented this explicitly: among patients with stage I rectal cancer, only 39% of Black patients underwent the primary curative procedure (proctectomy or proctocolectomy), compared to 64% of White patients. Research from the National Cancer Database has found that when Black patients do receive care at academic centers from surgeons who specialize in rectal cancer, their outcomes improve substantially — but the systemic barriers that prevent equitable access to that level of specialized care remain deeply entrenched.

The hopeful counterweight to these disparities is the measurable progress in treating advanced disease. The improvement in distant-stage rectal cancer survival from 8% to 18% since the mid-1990s — the largest survival gain in the entire CRC category according to the ACS Cancer Statistics 2026 report — reflects real advances in multimodal treatment including improved surgical techniques, better imaging-guided staging, refined chemotherapy regimens, new targeted therapies, and the gradual integration of immunotherapy, particularly for MSI-H/dMMR (microsatellite instability-high) rectal cancers that respond to checkpoint inhibitors. With more than 1.4 million CRC survivors living in the United States as of January 1, 2025, the combined impact of decades of treatment innovation is visible. The challenge for 2026 and beyond is ensuring that those innovations reach every patient equally — regardless of race, insurance status, geography, or age of diagnosis.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE